{"id":2220,"date":"2022-11-03T00:00:00","date_gmt":"2022-11-03T00:00:00","guid":{"rendered":"http:\/\/centogene.vl22350.dinaserver.com\/2220"},"modified":"2022-11-03T00:00:00","modified_gmt":"2022-11-03T00:00:00","slug":"centogene-launches-rare-and-neurodegenerative-disease-biodata-network","status":"publish","type":"post","link":"https:\/\/www.centogene.com\/pl\/centogene-launches-rare-and-neurodegenerative-disease-biodata-network\/","title":{"rendered":"CENTOGENE uruchamia sie\u0107 biodanych chor\u00f3b rzadkich i neurodegeneracyjnych"},"content":{"rendered":"<ul>\n<li>Company\u2019s launch of Biodata Network offers new portfolio of data-driven solutions<\/li>\n<li>Collaboration with BC Platforms increases access to data-driven genomic insights via Global Data Partner Network, BCRQUEST.com<\/li>\n<li>Tranche of 80,000 genetic sequences made accessible online for research and drug discovery<\/li>\n<\/ul>\n<p> <strong>CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, November 3, 2022 (GLOBE NEWSWIRE) \u2013<\/strong> Centogene NV (Nasdaq: CNTG), kluczowy partner w dziedzinie nauk przyrodniczych dostarczaj\u0105cy odpowiedzi opartych na danych na temat chor\u00f3b rzadkich i neurodegeneracyjnych, og\u0142osi\u0142 dzi\u015b globalne uruchomienie swojej sieci Biodata Network, portfolio rozwi\u0105za\u0144 partnerskich opartych na danych, obejmuj\u0105cych licencje Biodata i raporty Insight Reports, dla firm biofarmaceutycznych i instytucji badawczych.<\/p>\n<p>To offer increased access to CENTOGENE\u2019s unique data-driven insights, the Company has partnered with BC Platforms, a global leader in healthcare data management and analytics, to utilize their Global Data Partner Network, BCRQUEST.com. This integrated healthcare data platform creates a connected, secure data source for enabling partners access to datasets for the acceleration and de-risking of target &amp; drug discovery, as well as for optimizing clinical pipelines.<\/p>\n<p>The addition of these CENTOGENE datasets represents an estimated 20% increase in both the breadth and depth of genomic data currently available via BC Platforms. The dataset reflects a diverse geographic and ethnic sample base and includes a large share of pediatric cases in rare and neurodegenerative diseases, with data modalities including clinical, multiomic, and socio-demographic data. This dataset has been made available from the diverse CENTOGENE Biodatabank, which currently contains nearly 700,000 patients represented from over 120 countries, over 70% of whom are of non-European descent.<\/p>\n<p>\u201cAt CENTOGENE, we are committed to delivering data-driven, life-changing answers to accelerate and de-risk drug discovery, development, and commercialization,\u201d said Kim Stratton, Chief Executive Officer at CENTOGENE. \u201cBy partnering with BC Platforms and launching our Biodata Network Portfolio, we are extending our strategy and expanding our commercialization opportunities to provide partners with yet another model to work with us. Ultimately, we want to heal the world of rare and neurodegenerative diseases, and we believe offering greater access to the CENTOGENE Biodatabank will accelerate bringing potentially life-saving therapeutics to patients around the world.\u201d<\/p>\n<p>Tero Silvola, CEO of BC Platforms, said, \u201cThrough our partnership with CENTOGENE, one of the most experienced partners in the field, we are significantly advancing the way the medical community collaborates. With the diversity of our BCRQUEST.com global data network combined with CENTOGENE\u2019s Biodatabank, the medical community will now be able to tap into a rich source of insights on rare and neurodegenerative diseases to drive the healthcare of the future \u2013 benefitting patients globally.\u201d<\/p>\n<p>Bettina Goerner, CENTOGENE\u2019s Chief Data Officer, added, \u201c95% of rare diseases currently do not have an FDA-approved treatment. We see BC Platforms as our ideal partner for the secure and scalable solutions needed for the launch of our Biodata Network, so we can significantly expand the abilities of our partners around the world to drive drug discovery. Because of the generous consent given by patients who have contributed their data for research on rare and neurodegenerative diseases, we hope to offer real solutions to patients around the world.\u201d<\/p>\n<p>CENTOGENE has a life-long commitment to protecting the privacy of patients\u2019 data, which is secured and handled with the greatest level of care and in accordance with applicable regulations and laws, including but not limited to, GDPR. Every year, CENTOGENE processes thousands of genetic tests in the Company\u2019s state-of-the-art laboratories, while ensuring relevant compliances.<\/p>\n<h3>The CENTOGENE Biodata Network \u2013 Transforming Insights Into Answers<\/h3>\n<p>CENTOGENE\u2019s newly-launched Biodata Network portfolio of customizable data-driven partnering solutions includes:<\/p>\n<h4><span class=\"t3m-text-red\">Biodata Licenses<\/span><\/h4>\n<ul>\n<li>Biodata Licenses enable partners to securely access unique real-world datasets via BC Platform\u2019s cloud-based trusted research environment for self-analysis. Optional analysis support is also available<\/li>\n<\/ul>\n<h4><span class=\"t3m-text-red\">Raporty Insight<\/span><\/h4>\n<ul>\n<li>These tailored data analysis reports are generated in close consultation with biopharma partners and CENTOGENE\u2019s in-house geneticists, medical experts, and data scientists. This seamlessly enables institutions to answer ad hoc research questions via real-world data, which is carefully curated, analyzed, and summarized by CENTOGENE\u2019s team of experts<\/li>\n<\/ul>\n<h3>O firmie CENTOGENE<\/h3>\n<p>CENTOGENE\u2019s mission is to provide data-driven, life-changing answers to patients, physicians, and biopharma companies for rare and neurodegenerative diseases. We integrate multiomic technologies with the CENTOGENE Biodatabank \u2013 providing dimensional analysis to guide the next generation of precision medicine. Our unique approach enables rapid and reliable diagnosis for patients, supports a more precise physician understanding of disease states, and accelerates and de-risks targeted biopharma drug discovery, development, and commercialization.<\/p>\n<p>Since our founding in 2006, CENTOGENE has been offering rapid and reliable diagnosis \u2013 building a network of approximately 30,000 active physicians. Our ISO, CAP, and CLIA certified multiomic reference laboratories in Germany utilize Phenomic, Genomic, Transcriptomic, Epigenomic, Proteomic, and Metabolomic datasets. This diverse data is captured in our CENTOGENE Biodatabank, with nearly 700,000 patients represented from over 120 countries, over 70% of whom are of non-European descent. To date, the CENTOGENE Biodatabank has contributed to generating novel insights for more than 260 peer-reviewed publications.<\/p>\n<p>By translating our data and expertise into tangible insights, we have supported over 50 collaborations with biopharma partners. Together, we accelerate and de-risk drug discovery, development, and commercialization in target &amp; drug screening, clinical development, market access and expansion, as well as offering Biodata Licenses and Insight Reports to enable a world healed of all rare and neurodegenerative diseases.<\/p>\n<p>Aby dowiedzie\u0107 si\u0119 wi\u0119cej o naszych produktach, ofercie i celach ukierunkowanych na pacjent\u00f3w, odwied\u017a stron\u0119 <a href=\"t3:\/\/page?uid=1\" target=\"_top\" title=\"Strona internetowa CENTOGENE\">www.centogene.com<\/a> i \u015bled\u017a nas na <a href=\"https:\/\/www.linkedin.com\/company\/centogene\" title=\"CENTOGENE LinkedIn\">LinkedIn<\/a>.<\/p>\n<h3>About BC Platforms<\/h3>\n<p>BC Platforms is a global leader in building data networks for the life sciences industry and provides versatile technology platforms for personalised medicine, accelerating the translation of innovations into clinical practice. We convert complex biological information collected in the healthcare setting into actionable insights. With our innovative technology we are creating a patient centric infinity loop between the life sciences and healthcare sectors. Data we generate, harmonise, and manage, from diverse biobanks and healthcare institutions, is made accessible for pharmaceutical and biotech companies to enhance their core strengths in research and development. In parallel, we enable stratification of patients towards targeted therapies, delivering on the promise of more personalized healthcare.<\/p>\n<p>Our high performing genomic data discovery and analytics platform enables flexible data integration, secure analysis, and interpretation of molecular and clinical information. We have developed a Global Data Partner Network, BCRQUEST.com, which allows access to high-quality real-world data. This rapidly growing network has a footprint across many sites, including networks of major hospitals, covering 20 countries on five continents, providing standard of care data for over 23 million patients. Our platforms seamlessly facilitate access to highly enriched data for pharmaceutical research and development.<\/p>\n<p>Founded in 1997 from a MIT Whitehead project spinoff, we have a strong scientific heritage underpinned by over 25 years of working in close collaboration with a network of leading researchers, developers, and industry partners. We have global operations with our headquarters in Zurich, Switzerland, R&amp;D in Espoo, Finland, and Singapore, as well as a presence in London and Boston. For more information, visit our <a href=\"http:\/\/www.bcplatforms.com\/\" target=\"_blank\" title=\"BC Platforms Website\">website<\/a> i \u015bled\u017a nas na <a href=\"https:\/\/www.linkedin.com\/company\/bc-platforms\/\" target=\"_blank\" title=\"BC Platforms LinkedIn\">LinkedIn<\/a>.<\/p>\n<h3>O\u015bwiadczenia prognostyczne<\/h3>\n<p>Niniejsza informacja prasowa zawiera \u201co\u015bwiadczenia prognostyczne\u201d w rozumieniu federalnych przepis\u00f3w dotycz\u0105cych papier\u00f3w warto\u015bciowych w Stanach Zjednoczonych. Zawarte w niej o\u015bwiadczenia, kt\u00f3re nie maj\u0105 jednoznacznie historycznego charakteru, maj\u0105 charakter prognostyczny, a s\u0142owa \u201cprzewidywa\u0107\u201d, \u201cwierzy\u0107\u201d, \u201ckontynuowa\u0107\u201d, \u201coczekiwa\u0107\u201d, \u201cszacowa\u0107\u201d, \u201czamierza\u0107\u201d, \u201cprognozowa\u0107\u201d oraz podobne wyra\u017cenia i czasowniki w czasie przysz\u0142ym lub warunkowym, takie jak \u201cb\u0119dzie\u201d, \u201cby\u0142by\u201d, \u201cpowinien\u201d, \u201cm\u00f3g\u0142by\u201d, \u201cmo\u017ce\u201d, \u201cmo\u017ce\u201d i \u201cmo\u017ce\u201d, maj\u0105 na celu identyfikacj\u0119 o\u015bwiadcze\u0144 prognostycznych. Takie o\u015bwiadczenia prognostyczne wi\u0105\u017c\u0105 si\u0119 ze znanymi i nieznanymi ryzykami, niepewno\u015bciami i innymi istotnymi czynnikami, kt\u00f3re mog\u0105 spowodowa\u0107, \u017ce rzeczywiste wyniki, efektywno\u015b\u0107 lub osi\u0105gni\u0119cia CENTOGENE b\u0119d\u0105 istotnie r\u00f3\u017cni\u0107 si\u0119 od jakichkolwiek przysz\u0142ych wynik\u00f3w, efektywno\u015bci lub osi\u0105gni\u0119\u0107 wyra\u017conych lub dorozumianych w o\u015bwiadczeniach prognostycznych. Do takich ryzyk i niepewno\u015bci nale\u017c\u0105 m.in. negatywne warunki ekonomiczne i geopolityczne oraz niestabilno\u015b\u0107 i zmienno\u015b\u0107 \u015bwiatowych rynk\u00f3w finansowych, mo\u017cliwe zmiany w obowi\u0105zuj\u0105cych i proponowanych przepisach, regulacjach i politykach rz\u0105dowych, presja wynikaj\u0105ca ze wzrostu konkurencji i konsolidacji w naszej bran\u017cy, koszty i niepewno\u015b\u0107 zwi\u0105zana z zatwierdzeniem regulacyjnym, w tym przez Ameryka\u0144sk\u0105 Agencj\u0119 ds. \u017bywno\u015bci i Lek\u00f3w (FDA), nasze uzale\u017cnienie od stron trzecich i partner\u00f3w, w tym nasza zdolno\u015b\u0107 do zarz\u0105dzania wzrostem i nawi\u0105zywania nowych relacji z klientami, nasza zale\u017cno\u015b\u0107 od bran\u017cy chor\u00f3b rzadkich, nasza zdolno\u015b\u0107 do zarz\u0105dzania ekspansj\u0105 mi\u0119dzynarodow\u0105, nasza zale\u017cno\u015b\u0107 od kluczowego personelu, nasza zale\u017cno\u015b\u0107 od ochrony w\u0142asno\u015bci intelektualnej, wahania naszych wynik\u00f3w operacyjnych spowodowane wp\u0142ywem kurs\u00f3w walutowych, nasza zdolno\u015b\u0107 do usprawnienia wykorzystania got\u00f3wki, nasze zapotrzebowanie na dodatkowe finansowanie lub inne czynniki. Aby uzyska\u0107 wi\u0119cej informacji na temat ryzyka i niepewno\u015bci, kt\u00f3re mog\u0105 spowodowa\u0107, \u017ce rzeczywiste wyniki b\u0119d\u0105 si\u0119 r\u00f3\u017cni\u0107 od tych wyra\u017conych w niniejszych o\u015bwiadczeniach prognostycznych, a tak\u017ce ryzyka zwi\u0105zanego z dzia\u0142alno\u015bci\u0105 CENTOGENE og\u00f3lnie, zapoznaj si\u0119 z czynnikami ryzyka CENTOGENE przedstawionymi w Formularzu 20-F z\u0142o\u017conym przez CENTOGENE 31 marca 2022 r. w Komisji Papier\u00f3w Warto\u015bciowych i Gie\u0142d (SEC) oraz w p\u00f3\u017aniejszych dokumentach z\u0142o\u017conych w SEC. Wszelkie o\u015bwiadczenia prognostyczne zawarte w niniejszym komunikacie prasowym obowi\u0105zuj\u0105 wy\u0142\u0105cznie na dzie\u0144 jego sporz\u0105dzenia, a CENTOGENE wyra\u017anie zrzeka si\u0119 obowi\u0105zku aktualizacji jakichkolwiek o\u015bwiadcze\u0144 prognostycznych, niezale\u017cnie od tego, czy wynika to z nowych informacji, przysz\u0142ych zdarze\u0144, czy z innych przyczyn.<\/p>\n<h5>Kontakt dla medi\u00f3w: &nbsp;<\/h5>\n<p>CENTOGENE<\/p>\n<p>Ben Legg<br \/> Komunikacja korporacyjna&nbsp;<br \/> <a href=\"mailto:press@centogene.com\" title=\"Napisz e-mail\">press(at)centogene(dot)com<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Centogene NV (Nasdaq: CNTG), kluczowy partner w dziedzinie nauk przyrodniczych dostarczaj\u0105cy odpowiedzi opartych na danych na temat chor\u00f3b rzadkich i neurodegeneracyjnych, og\u0142osi\u0142 dzi\u015b globalne uruchomienie swojej sieci Biodata Network, portfolio rozwi\u0105za\u0144 partnerskich opartych na danych, obejmuj\u0105cych licencje Biodata i raporty Insight Reports, dla firm biofarmaceutycznych i instytucji badawczych.<\/p>","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-2220","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CENTOGENE Launches Rare and Neurodegenerative Disease Biodata Network | CENTOGENE<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.centogene.com\/pl\/centogene-launches-rare-and-neurodegenerative-disease-biodata-network\/\" \/>\n<meta property=\"og:locale\" content=\"pl_PL\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CENTOGENE Launches Rare and Neurodegenerative Disease Biodata Network | CENTOGENE\" \/>\n<meta property=\"og:description\" content=\"Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the global launch of its Biodata Network, a portfolio of data-driven partnering solutions, including Biodata Licenses and Insight Reports, for biopharma and research institutions.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.centogene.com\/pl\/centogene-launches-rare-and-neurodegenerative-disease-biodata-network\/\" \/>\n<meta property=\"og:site_name\" content=\"CENTOGENE\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-03T00:00:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.centogene.com\/wp-content\/uploads\/2025\/03\/csm_centogene-diagnostics-priority-disease-03_5a57c07603.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"740\" \/>\n\t<meta property=\"og:image:height\" content=\"416\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"admincg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Napisane przez\" \/>\n\t<meta name=\"twitter:data1\" content=\"admincg\" \/>\n\t<meta name=\"twitter:label2\" content=\"Szacowany czas czytania\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-launches-rare-and-neurodegenerative-disease-biodata-network\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-launches-rare-and-neurodegenerative-disease-biodata-network\\\/\"},\"author\":{\"name\":\"admincg\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/person\\\/d9b8738539a9ddb5de5a02a909d40b8b\"},\"headline\":\"CENTOGENE Launches Rare and Neurodegenerative Disease Biodata Network\",\"datePublished\":\"2022-11-03T00:00:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-launches-rare-and-neurodegenerative-disease-biodata-network\\\/\"},\"wordCount\":1504,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#organization\"},\"articleSection\":[\"Uncategorized\"],\"inLanguage\":\"pl-PL\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.centogene.com\\\/centogene-launches-rare-and-neurodegenerative-disease-biodata-network\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-launches-rare-and-neurodegenerative-disease-biodata-network\\\/\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/centogene-launches-rare-and-neurodegenerative-disease-biodata-network\\\/\",\"name\":\"CENTOGENE Launches Rare and Neurodegenerative Disease Biodata Network | CENTOGENE\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#website\"},\"datePublished\":\"2022-11-03T00:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-launches-rare-and-neurodegenerative-disease-biodata-network\\\/#breadcrumb\"},\"inLanguage\":\"pl-PL\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.centogene.com\\\/centogene-launches-rare-and-neurodegenerative-disease-biodata-network\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-launches-rare-and-neurodegenerative-disease-biodata-network\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.centogene.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CENTOGENE Launches Rare and Neurodegenerative Disease Biodata Network\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#website\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/\",\"name\":\"CENTOGENE\",\"description\":\"Guiding Precision Medicine\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.centogene.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pl-PL\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#organization\",\"name\":\"CENTOGENE\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pl-PL\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/CENTOGENE-Flower.png\",\"contentUrl\":\"https:\\\/\\\/www.centogene.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/CENTOGENE-Flower.png\",\"width\":246,\"height\":246,\"caption\":\"CENTOGENE\"},\"image\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/centogene\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UClZxtN_laC1_ZtCdxkasdPQ\",\"https:\\\/\\\/www.instagram.com\\\/_centogene_\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/person\\\/d9b8738539a9ddb5de5a02a909d40b8b\",\"name\":\"admincg\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/pl\\\/author\\\/admincg\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CENTOGENE Launches Rare and Neurodegenerative Disease Biodata Network | CENTOGENE","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.centogene.com\/pl\/centogene-launches-rare-and-neurodegenerative-disease-biodata-network\/","og_locale":"pl_PL","og_type":"article","og_title":"CENTOGENE Launches Rare and Neurodegenerative Disease Biodata Network | CENTOGENE","og_description":"Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the global launch of its Biodata Network, a portfolio of data-driven partnering solutions, including Biodata Licenses and Insight Reports, for biopharma and research institutions.","og_url":"https:\/\/www.centogene.com\/pl\/centogene-launches-rare-and-neurodegenerative-disease-biodata-network\/","og_site_name":"CENTOGENE","article_published_time":"2022-11-03T00:00:00+00:00","og_image":[{"width":740,"height":416,"url":"https:\/\/www.centogene.com\/wp-content\/uploads\/2025\/03\/csm_centogene-diagnostics-priority-disease-03_5a57c07603.webp","type":"image\/webp"}],"author":"admincg","twitter_card":"summary_large_image","twitter_misc":{"Napisane przez":"admincg","Szacowany czas czytania":"7 minut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.centogene.com\/centogene-launches-rare-and-neurodegenerative-disease-biodata-network\/#article","isPartOf":{"@id":"https:\/\/www.centogene.com\/centogene-launches-rare-and-neurodegenerative-disease-biodata-network\/"},"author":{"name":"admincg","@id":"https:\/\/www.centogene.com\/#\/schema\/person\/d9b8738539a9ddb5de5a02a909d40b8b"},"headline":"CENTOGENE Launches Rare and Neurodegenerative Disease Biodata Network","datePublished":"2022-11-03T00:00:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.centogene.com\/centogene-launches-rare-and-neurodegenerative-disease-biodata-network\/"},"wordCount":1504,"commentCount":0,"publisher":{"@id":"https:\/\/www.centogene.com\/#organization"},"articleSection":["Uncategorized"],"inLanguage":"pl-PL","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.centogene.com\/centogene-launches-rare-and-neurodegenerative-disease-biodata-network\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.centogene.com\/centogene-launches-rare-and-neurodegenerative-disease-biodata-network\/","url":"https:\/\/www.centogene.com\/centogene-launches-rare-and-neurodegenerative-disease-biodata-network\/","name":"CENTOGENE Launches Rare and Neurodegenerative Disease Biodata Network | CENTOGENE","isPartOf":{"@id":"https:\/\/www.centogene.com\/#website"},"datePublished":"2022-11-03T00:00:00+00:00","breadcrumb":{"@id":"https:\/\/www.centogene.com\/centogene-launches-rare-and-neurodegenerative-disease-biodata-network\/#breadcrumb"},"inLanguage":"pl-PL","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.centogene.com\/centogene-launches-rare-and-neurodegenerative-disease-biodata-network\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.centogene.com\/centogene-launches-rare-and-neurodegenerative-disease-biodata-network\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.centogene.com\/"},{"@type":"ListItem","position":2,"name":"CENTOGENE Launches Rare and Neurodegenerative Disease Biodata Network"}]},{"@type":"WebSite","@id":"https:\/\/www.centogene.com\/#website","url":"https:\/\/www.centogene.com\/","name":"CENTOGENE","description":"Kierowanie medycyn\u0105 precyzyjn\u0105","publisher":{"@id":"https:\/\/www.centogene.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.centogene.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pl-PL"},{"@type":"Organization","@id":"https:\/\/www.centogene.com\/#organization","name":"CENTOGENE","url":"https:\/\/www.centogene.com\/","logo":{"@type":"ImageObject","inLanguage":"pl-PL","@id":"https:\/\/www.centogene.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.centogene.com\/wp-content\/uploads\/2026\/04\/CENTOGENE-Flower.png","contentUrl":"https:\/\/www.centogene.com\/wp-content\/uploads\/2026\/04\/CENTOGENE-Flower.png","width":246,"height":246,"caption":"CENTOGENE"},"image":{"@id":"https:\/\/www.centogene.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/centogene","https:\/\/www.youtube.com\/channel\/UClZxtN_laC1_ZtCdxkasdPQ","https:\/\/www.instagram.com\/_centogene_\/"]},{"@type":"Person","@id":"https:\/\/www.centogene.com\/#\/schema\/person\/d9b8738539a9ddb5de5a02a909d40b8b","name":"admincg","url":"https:\/\/www.centogene.com\/pl\/author\/admincg\/"}]}},"_links":{"self":[{"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/posts\/2220","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/comments?post=2220"}],"version-history":[{"count":0,"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/posts\/2220\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/media?parent=2220"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/categories?post=2220"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/tags?post=2220"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}